Together, our findings demonstrate that augmentation of chemokines that recruit protective CCR4+ CD4+ T cells, while blocking chemokines that recruit detrimental CCR6+ CD4+ T cells, may constitute a novel approach for IPF therapy. The gene discussed is CCR4; the disease is idiopathic pulmonary fibrosis.